Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study.
Cognition
Mobility
Motor symptoms
Parkinson’s disease
Photobiomodulation
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
02 Jul 2021
02 Jul 2021
Historique:
received:
28
11
2020
accepted:
18
05
2021
entrez:
3
7
2021
pubmed:
4
7
2021
medline:
17
7
2021
Statut:
epublish
Résumé
Parkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons. To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT). Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%. Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed. PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted. Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p , registered on 12/01/2018.
Sections du résumé
BACKGROUND
BACKGROUND
Parkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons.
OBJECTIVE
OBJECTIVE
To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT).
METHODS
METHODS
Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%.
RESULTS
RESULTS
Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed.
CONCLUSIONS
CONCLUSIONS
PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted.
TRIAL REGISTRATION
BACKGROUND
Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p , registered on 12/01/2018.
Identifiants
pubmed: 34215216
doi: 10.1186/s12883-021-02248-y
pii: 10.1186/s12883-021-02248-y
pmc: PMC8249215
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
256Références
Photochem Photobiol. 2018 Mar;94(2):199-212
pubmed: 29164625
Phys Ther. 2005 Feb;85(2):134-41
pubmed: 15679464
J Neurol. 2019 Aug;266(8):1927-1936
pubmed: 31073716
Control Clin Trials. 1989 Dec;10(4):407-15
pubmed: 2691207
J Neurol. 2001 Nov;248(11):950-8
pubmed: 11757958
Mov Disord. 1998;13 Suppl 3:85-9
pubmed: 9827601
Parkinsonism Relat Disord. 2011 Jan;17(1):1-9
pubmed: 20833572
Brain Pathol. 2010 May;20(3):633-9
pubmed: 20522088
Hum Mov Sci. 2011 Aug;30(4):783-91
pubmed: 21339012
Photobiomodul Photomed Laser Surg. 2019 Oct;37(10):651-656
pubmed: 31647774
Cureus. 2018 Oct 22;10(10):e3474
pubmed: 30648026
J Appl Biomech. 2015 Jun;31(3):189-94
pubmed: 25536440
Neuroscience. 2019 Dec 1;422:161-171
pubmed: 31682952
J Parkinsons Dis. 2020;10(4):1343-1353
pubmed: 32986683
Phys Ther. 2001 Feb;81(2):810-8
pubmed: 11175678
Nat Rev Neurosci. 2020 Feb;21(2):103-115
pubmed: 31907406
Exp Brain Res. 2017 Oct;235(10):3081-3092
pubmed: 28744621
Photobiomodul Photomed Laser Surg. 2019 Mar;37(3):159-167
pubmed: 31050946
Lancet Neurol. 2016 Jun;15(7):736-747
pubmed: 27106073
Dement Neuropsychol. 2016 Oct-Dec;10(4):280-286
pubmed: 29213470
Sci Rep. 2015 Jun 01;5:10581
pubmed: 26030745
J Comp Neurol. 2010 Jan 1;518(1):25-40
pubmed: 19882716
Photobiomodul Photomed Laser Surg. 2019 Oct;37(10):615-622
pubmed: 31536464
Med Hypotheses. 2014 Mar;82(3):275-81
pubmed: 24424395
J Clin Epidemiol. 2014 Mar;67(3):267-77
pubmed: 24275499
Brain Stimul. 2019 May - Jun;12(3):810-812
pubmed: 30824206
Nord J Psychiatry. 2018 Aug;72(6):442-446
pubmed: 30744517
J Photochem Photobiol B. 2020 Jul;208:111916
pubmed: 32480201
Parkinsonism Relat Disord. 2019 Sep;66:265-266
pubmed: 31445904
Photobiomodul Photomed Laser Surg. 2019 Oct;37(10):623-634
pubmed: 31647776
Alzheimers Res Ther. 2014 Jan 03;6(1):2
pubmed: 24387311
J Neurol Neurosci. 2017;8(1):
pubmed: 28593105
Curr Drug Targets. 2014;15(10):943-7
pubmed: 25174438
Med J Aust. 2018 May 21;208(9):404-409
pubmed: 29764353
J Geriatr Phys Ther. 2016 Oct-Dec;39(4):165-70
pubmed: 26428902
Expert Opin Investig Drugs. 2020 Jul;29(7):685-695
pubmed: 32419521
Int J Geriatr Psychiatry. 2019 Feb;34(2):369-377
pubmed: 30474306
Drugs. 2019 Apr;79(6):593-608
pubmed: 30905034
Lancet Neurol. 2018 Nov;17(11):928-929
pubmed: 30287052
Lasers Med Sci. 2014 Mar;29(2):709-15
pubmed: 23873594
Neural Regen Res. 2019 Dec;14(12):2086-2087
pubmed: 31397343
J Neurotrauma. 2014 Jun 1;31(11):1008-17
pubmed: 24568233
Photomed Laser Surg. 2018 Oct;36(10):515-517
pubmed: 30234428
Med Care. 2003 May;41(5):593-6
pubmed: 12719682
Mov Disord. 2019 Oct;34(10):1480-1487
pubmed: 31291488
Behav Brain Funct. 2009 Dec 08;5:46
pubmed: 19995444
Neurophotonics. 2016 Jul;3(3):031404
pubmed: 26989758
Mov Disord. 2019 Feb;34(2):180-198
pubmed: 30653247
Neurophotonics. 2016 Jan;3(1):015003
pubmed: 26835486
Neural Regen Res. 2015 Mar;10(3):349-51
pubmed: 25878572
J Neurol Phys Ther. 2011 Dec;35(4):157-63
pubmed: 22020457
Int J Gen Med. 2014 Jul 21;7:383-8
pubmed: 25092996
Photomed Laser Surg. 2016 Nov;34(11):516-524
pubmed: 26741110
Trends Neurosci. 2002 Jun;25(6):302-6
pubmed: 12086748
J Bodyw Mov Ther. 2019 Oct;23(4):690-694
pubmed: 31733748
J Parkinsons Dis. 2018;8(s1):S31-S39
pubmed: 30584161
Lasers Med Sci. 2020 Aug;35(6):1253-1262
pubmed: 31782023
FASEB J. 2020 Mar;34(3):3616-3630
pubmed: 31957088
Neural Regen Res. 2017 Apr;12(4):574-575
pubmed: 28553332
Photomed Laser Surg. 2017 Aug;35(8):432-441
pubmed: 28186867
Ageing Res Rev. 2017 Aug;37:69-78
pubmed: 28552720
Sci Rep. 2019 Apr 19;9(1):6309
pubmed: 31004126
Biomed Eng Online. 2020 May 11;19(1):29
pubmed: 32393271
Mov Disord. 2019 Sep;34(9):1243-1251
pubmed: 31291491
Biomolecules. 2020 Apr 15;10(4):
pubmed: 32326425
Neuroscience. 2019 Feb 21;400:85-97
pubmed: 30625333
Prog Neurobiol. 2019 Jun;177:73-93
pubmed: 30219247
BMJ Open. 2012 Jun 25;2(3):
pubmed: 22734114
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
J Phys Ther Sci. 2015 Dec;27(12):3675-9
pubmed: 26834330
Arch Clin Neuropsychol. 2020 Jul 17;:
pubmed: 32681175
Parkinsons Dis. 2013;2013:987621
pubmed: 23841022
Phys Ther. 2000 Sep;80(9):896-903
pubmed: 10960937
Mov Disord. 2018 Aug;33(8):1248-1266
pubmed: 29570866
Pain. 2006 Sep;124(1-2):201-10
pubmed: 16806710
J Clin Neurosci. 2019 Mar;61:174-179
pubmed: 30385169
Neurol Res. 2008 Jun;30(5):493-6
pubmed: 18241530
J Parkinsons Dis. 2020;10(3):899-902
pubmed: 32390643
Mov Disord. 2008 May 15;23(7):1043-1046
pubmed: 18381646
Phys Ther. 1998 Jun;78(6):577-92
pubmed: 9626270
AIMS Biophys. 2017;4(3):337-361
pubmed: 28748217